NBIX — Neurocrine Biosciences Share News
0.000.00%
Last trade - 00:00- $13.92bn
- $13.53bn
- $2.86bn
Brief: Neurocrine Biosciences Announces Initiation Of Phase 1 Clinical Study Evaluating NBI-1140675
Brief: Neurocrine Biosciences Board Of Directors Authorizes $500 Million Share Repurchase Program
U.S. STOCKS ON THE MOVE-McDonald, Uber, SolarWinds
U.S. STOCKS ON THE MOVE-Byrna Technologies, Xcel Energy
Neurocrine falls after analysts say forecast for key drug 'conservative'
U.S. RESEARCH ROUNDUP-Altus Power, Amazon, Nevro
Neurocrine Biosciences Inc reports results for the quarter ended December 31 - Earnings Summary
Brief: Neurocrine Biosciences Q4 Adjusted EPS USD 1.69 Vs. IBES Estimate USD 1.56
Brief: Andrew Ratz, Ph.D., Joins Neurocrine Biosciences As Senior Vice President Of Drug Development, Delivery And Device
U.S. RESEARCH ROUNDUP- Capital One Financial, Netflix, Regeneron Pharmaceuticals
Brief: Neurocrine Biosciences Announces Publication On Traditional Glucocorticoid Treatment In Classic Congenital Adrenal Hyperplasia
U.S. RESEARCH ROUNDUP-Hershey, Paychex, Revvity
U.S. RESEARCH ROUNDUP- Domino's Pizza, Honeywell, Walmart
US FDA approves Neurocrine Biosciences' genetic disorder drug (updated)
US FDA approves Neurocrine Biosciences' genetic disorder drug
U.S. RESEARCH ROUNDUP-Cable One, Neurogene, Topbuild
Brief: Neurocrine Biosciences Got Into Accelerated Share Repurchase Transaction To Repurchase $300 Million Of Shares Of Co's Common Stock
Neurocrine Biosciences Inc reports results for the quarter ended in September 30 - Earnings Summary
Brief: Neurocrine Biosciences Q3 Adjusted EPS USD 1.81 Vs. IBES Estimate USD 1.51